29367
document
[ The effects of mexicor on thrombocyte aggregation , blood viscosity , hemodynamics , and the clinical course of coronary artery disease ] . The authors analyze their experience in the application of mexicor , a Russian cytoprotector , in 50patients with chronic coronary artery disease ( CAD ) and 51 patients with acute coronary syndrome . In additional to cytoprotective action , the use of mexidor in complex therapy of CAD lowers the functional activity of thrombocytes , eliminates high blood viscosity syndrome , and lowers low density lipoprotein cholesterol level . These favorable changes in hemorheological parameters improves myocardial perfusion , lowers the strength and frequency of coronary pain attacks , retards postinfarction left ventricular remodeling , and increases the quality of life of patients with various CAD forms .
29368
Intervention_Pharmacological
mexicor
29369
Intervention_Pharmacological
mexicor
29370
Intervention_Physical
, a Russian cytoprotector
29371
Intervention_Pharmacological
mexidor
29372
Outcome_Physical
thrombocyte aggregation
29373
Outcome_Physical
blood viscosity
29374
Outcome_Physical
hemodynamics
29375
Outcome_Physical
functional activity of thrombocytes
29376
Outcome_Physical
high blood viscosity syndrome
29377
Outcome_Physical
low density lipoprotein cholesterol level
29378
Outcome_Physical
myocardial perfusion
29379
Outcome_Physical
strength and frequency of coronary pain attacks
29380
Outcome_Physical
postinfarction left ventricular remodeling
29381
Outcome_Other
quality of life of patients
29382
Participant_Sample-size
50patients
29383
Participant_Condition
chronic coronary artery disease ( CAD )
29384
Participant_Sample-size
51 patients
29385
Participant_Condition
acute coronary syndrome